Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a research report sent to investors on Wednesday.

A number of other equities research analysts have also weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a report on Thursday, October 31st. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.

Abeona Therapeutics Price Performance

Shares of Abeona Therapeutics stock opened at $5.75 on Wednesday. The business’s 50-day moving average price is $6.19 and its 200-day moving average price is $5.27. The firm has a market capitalization of $249.95 million, a PE ratio of -2.14 and a beta of 1.52. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $9.01. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31.

Hedge Funds Weigh In On Abeona Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rosalind Advisors Inc. boosted its holdings in Abeona Therapeutics by 4.7% in the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock valued at $11,578,000 after acquiring an additional 82,000 shares in the last quarter. Western Standard LLC increased its position in shares of Abeona Therapeutics by 7.0% during the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after buying an additional 110,998 shares during the period. Citigroup Inc. increased its position in shares of Abeona Therapeutics by 10.1% during the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 56,332 shares during the period. Renaissance Technologies LLC raised its stake in Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after buying an additional 429,456 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Abeona Therapeutics by 21.7% in the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after buying an additional 83,050 shares during the period. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.